PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter

Mads Hald Andersen

In a very important recent study, Chen and colleagues describe that PD-L1 (B7-H1, CD274) is expressed on both malignant cells and infiltrating macrophages in a subset of aggressive B-cell lymphomas (1). The article highlights the possibilities of targeting the PD-1/PD-L1 pathway in these malignancies. Interactions between PD-1 on T cells and the ligand PD-L1 (B7-H1) control the induction and maintenance of peripheral T-cell tolerance during normal immune responses. Accordingly, tumor-infiltrating lymphocytes are inhibited by PD-L1 at the tumor site because of elevated levels of PD-1 on the surface of such T cells. Indeed, blockade of either PD-1 or PD-L1 resulted in objective clinical responses (2). Remarkably, an association between objective clinical response and PD-L1 expression on tumor cells was described (2). Taube and colleagues furthermore recently described that T cells may actually trigger their own inhibition by secreting cytokines that drive tumor PD-L1 expression (3). However, the immune system itself seems also to have established a respective counteractive mechanism, that is, PD-L1-specific, CD8⁺, cytotoxic T cells. Thus, PD-L1-reactive T cells can readily be isolated from peripheral blood of patients with cancer (melanoma) and to a lesser extent from blood of healthy donors (4). These PD-L1-specific T cells not only recognized and killed melanoma cells as well as cutaneous T-cell lymphoma cells, but also additionally PD-L1-expressing antigen-presenting cell (APC) in a PD-L1-dependent manner (4, 5). PD-L1 can furthermore be internalized, processed, and cross-presented on the cell surface by APC. This is notable, because soluble PD-L1 has been detected in the sera from patients with cancer. Thus, induction of PD-L1-specific T cells should boost immunity by killing of immune suppressive tumor cells as well as PD-L1-expressing stroma cells contributing to the permissive microenvironment. There is a major difference between blocking PD-L1 (or PD-1) function by antibody therapy, and generating a human leukocyte antigen-restricted T-cell response against processed and thus derived PD-L1 epitopes. PD-L1 antibodies target surface protein, whereas PD-L1-specific T cells recognize and kill cells, which are expressing PD-L1 epitopes on the surface derived from intracellular PD-L1.

It is important to note that PD-L1 additionally is expressed on normal immune cells, and is further upregulated upon activation in response to, for example, IFNγ. Nevertheless, PD-L1-specific T cells may be immensely useful to exploit for immunotherapy against certain cancers. Although not directly related, the publication by Chen and colleagues identifies a group of cancers with vigorous PD-L1 expression that may be suitable targets for such specific immunotherapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Support
This work was supported by Herlev Hospital, Novo Nordisk Foundation, Lundbeck foundation, Danish Cancer Society, and Danish Medical Research Council.

Received May 17, 2013; revised May 29, 2013; accepted May 29, 2013; published OnlineFirst June 20, 2013.

References
PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter

Mads Hald Andersen

*Clin Cancer Res* Published OnlineFirst June 20, 2013.

Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-1363

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.